Key result
Intravenous abciximab achieved successful thrombolysis in all 3 patients with established thrombi associated with atherosclerotic stenosis of a supra-aortic artery.
Why the study?
Does intravenous abciximab achieve thrombolysis in patients with refractory thrombus associated with atherosclerotic stenosis of a supra-aortic artery?
Case Report (n=3)
Does intravenous abciximab achieve thrombolysis in patients with refractory thrombus associated with atherosclerotic stenosis of a supra-aortic artery?
Intravenous abciximab successfully achieved thrombolysis in three patients with established supra-aortic artery thrombi refractory to previous antithrombotic treatments.
May support abciximab in refractory supra-aortic thrombi; leaves open need for prospective trials before adoption.
Abciximab was administered intravenously to three patients to treat thrombus associated with atherosclerotic stenosis of a supra-aortic artery. In two cases, the thrombi had been identified on a previous angiography more than a week before treatment. Successful thrombolysis was achieved with abciximab in all three cases. In this small series, abciximab had a thrombolytic effect on established thrombi that were refractory to previous antithrombotic treatment attempts.
No takes yet. Share an insight, caveat, or question.
Houdart et al. (2001) conducted a case report in Thrombus associated with atherosclerotic stenosis of a supra-aortic artery (n=3). Abciximab was evaluated on Successful thrombolysis. Intravenous abciximab achieved successful thrombolysis in all 3 patients with established thrombi associated with atherosclerotic stenosis of a supra-aortic artery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: